PubMed · 12498014
Avinza Elan.
Abstract
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 h. It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Marilyn R Semenchuk. 2002. Avinza Elan.. https://pubmed.ncbi.nlm.nih.gov/12498014/
Cite the original work for its findings. Save a collection to share your selection of sources.